✦ LIBER ✦

PSS15 THE COST-EFFECTIVENESS OF RANIBIZUMAB (LUCENTIS®) IN TREATING PATIENTS WITH PREDOMINANTLY CLASSIC, MINIMALLY CLASSIC, AND OCCULT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD)

✍ Scribed by A Turpcu; JW Hay

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PSS13 COST-EFFECTIVE ANALYSIS OF PEGAPTA

✍ LY Lu; W McGhan 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Using contrast sensitivity to estimate t

✍ Bansback, N; Davis, S; Brazier, J 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 203 KB

PSS10 Cost- Effectiveness of Ranibizumab

✍ Arreola-Ornelas, H.; Rosado-Buzzo, A.; García-Mollinedo, L.; Dorantes-Aguilar, J 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB